project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9NI; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.9; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.14; rna integrity number: 7.2; age at index: 73; days to birth: -26697; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1940; age at diagnosis: 26697; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 132.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 139; initial weight: 160.0; sample id: c73b6467-a0df-4a95-8917-34860f04d92b; sample submitter id: TCGA-ZG-A9NI-01A; portion id: c248673a-c1d4-4396-922a-cb89dafbed42; portion submitter id: TCGA-ZG-A9NI-01A-11; slide id: 116f3646-19fa-4a74-b2bb-f4b677b0f3fa; slide submitter id: TCGA-ZG-A9NI-01A-01-TSA; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 1.0; percent normal cells: 3.0; percent stromal cells: 17.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0; section location: TOP;